Skip to main
MRUS
MRUS logo

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 19%
Buy 13%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV has received a significant acquisition offer from Genmab, valued at approximately $8 billion, which represents a 41% premium over its closing share price and effectively mitigates FDA regulatory risk. The merger strategically enhances Genmab's pipeline with Merus' advanced bispecific antibody candidates, particularly petosemtamab, which holds strong potential for rapid commercialization and is anticipated to contribute substantially to revenue growth by 2029. With this acquisition, both companies are poised to leverage their expertise in multispecific antibodies, supporting a robust long-term growth strategy in the competitive biotechnology sector.

Bears say

Merus NV has faced a downgrade to Neutral due to the proposed acquisition by Genmab, which is set at a value of approximately $8 billion and is expected to close in early Q1 2026. The adjustment in price target from $109 to $97 per share reflects the transactional value and indicates a belief that higher acquisition bids are unlikely to materialize. Additionally, Genmab's financial strategy for the acquisition, involving substantial debt financing and a commitment to deleverage, adds a layer of uncertainty regarding Merus’s future financial stability and risk profile.

Merus (MRUS) has been analyzed by 16 analysts, with a consensus rating of Hold. 19% of analysts recommend a Strong Buy, 13% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Hold based on their latest research and market trends.

According to 16 analysts, Merus (MRUS) has a Hold consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.